Clinical and haemostatic effects of intravenous prostaglandin E1 therapy in patients with peripheral arterial occlusive disease.

Abstract

BACKGROUND:

In this study the action of an antiaggregatory prostaglandin, PGE1, was studied in a group of patients with peripheral arterial occlusive disease (PAOD).

METHODS:

In 16 patients with PAOD Fontaine stage IIb and III the clinical and haemostatic effects of the endovenous administration of 60 micrograms/die of alprostadil-PGE1 for four weeks, were evaluated. Before and after pharmacological treatment, were evaluated the clinical symptoms (claudicatio intermittens and rest pain) and the following haemostatic parameters: plasma thrombomodulin (TM), beta-thromboglobulin (beta-TG), D-dimer (DD), tissue-type plasminogen activator (t-PA) and plasminogen activator-inhibitor (PAI-1).

RESULTS:

No significant difference in plasma TM, t-PA and PAI-1 levels was observed after the treatment. On the other hand the patients showed plasma levels of beta-TG and DD significantly decreased at the end of the treatment. From the clinical point of view both claudicatio intermittens and rest pain satisfactorily improved in all patients.

CONCLUSIONS:

This data confirmed the therapeutic efficacy of PGE1 in the treatment of PAOD patients.

• Authors: A Trifiletti, R Scamardi, M A Pizzoleo, G Sottilotta, S Soraci, A Attinà, L Bagnato, N Barbera
• Journal: Panminerva medica (Panminerva Med) Vol. 41 Issue 1 Pg. 15-7 (Mar 1999) ISSN: 0031-0808 [Print] Italy
• PMID: 10230250 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Alprostadil

Topics

• Aged
• Alprostadil (therapeutic use)
• Arterial Occlusive Diseases (drug therapy)
• Female
• Hemostasis (physiology)
• Humans
• Injections, Intravenous
• Male
• Middle Aged